The Centers for Medicare & Medicaid Services (CMS) has finalized new reimbursement rates for Caristo Diagnostics' CaRi-Plaque™, an artificial intelligence-powered coronary plaque analysis performed on coronary CT angiography (CCTA) scans. Effective January 1, 2026, hospitals, imaging centers, and physicians will receive a standardized Medicare reimbursement rate of $950.50 under the Hospital Outpatient Prospective Payment System (OPPS) for this advanced diagnostic tool. This move marks a significant milestone in the integration of AI-driven technologies into routine cardiovascular diagnostics, providing a unified financial pathway for providers across both hospital and office-based settings.

CaRi-Plaque™ leverages proprietary AI algorithms to analyze CCTA scans and quantify coronary plaque burden, offering clinicians a more precise and objective assessment of atherosclerotic disease. The technology is designed to enhance risk stratification, guide treatment decisions, and improve patient outcomes by identifying high-risk plaque features that may not be apparent through conventional imaging. With the new reimbursement codes, hospitals and imaging centers can now confidently invest in and deploy this technology, knowing that Medicare will cover the cost of the analysis for eligible patients.

The finalized reimbursement rates are expected to accelerate the adoption of AI-powered plaque analysis in clinical practice, particularly in cardiology and radiology departments. By standardizing payment across settings, CMS is removing a key barrier to widespread implementation, which has previously been hindered by inconsistent or non-existent reimbursement policies. This development is especially relevant for hospitals seeking to expand their cardiovascular diagnostic capabilities and improve the efficiency of patient care pathways.

Caristo Diagnostics has positioned CaRi-Plaque™ as a transformative tool in the fight against cardiovascular disease, which remains the leading cause of death in the United States. The company's technology has been validated in multiple clinical studies, demonstrating its ability to predict future cardiovascular events with greater accuracy than traditional risk assessment methods. The new reimbursement framework will enable more hospitals to offer this advanced diagnostic service, potentially leading to earlier interventions and better outcomes for patients at risk of heart attack and stroke.

From a healthcare management perspective, the adoption of AI-powered plaque analysis presents both opportunities and challenges. On one hand, it offers the potential to improve diagnostic accuracy, reduce unnecessary procedures, and optimize resource utilization. On the other hand, hospitals will need to invest in the necessary infrastructure, including compatible imaging equipment, data storage solutions, and staff training, to fully leverage the technology. Additionally, providers will need to navigate the evolving regulatory landscape and ensure compliance with Medicare billing requirements.

The CMS decision reflects a broader trend toward the integration of AI and machine learning into clinical workflows, driven by the promise of improved patient outcomes and operational efficiencies. As more AI-powered diagnostic tools receive regulatory approval and reimbursement, hospitals and health systems will be increasingly called upon to evaluate and adopt these technologies in a strategic and evidence-based manner. The reimbursement for CaRi-Plaque™ sets a precedent for future AI-driven innovations in cardiology and beyond, signaling CMS's commitment to supporting the adoption of advanced diagnostic technologies that can enhance the quality and value of patient care.

Report Abuse